RESEARCH MONOGRAPH · KDC-MN-362

Landogrozumab

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

56/100

Another anti-myostatin antibody that demonstrated the pathway in humans without quite delivering meaningful function gains

Landogrozumab (LY2495655) is Eli Lilly's anti-myostatin entry, and it occupies roughly the same conceptual slot as domagrozumab and stamulumab: humanized antibody, selective for mature myostatin, designed to produce muscle hypertrophy without the broader ActRII ligand sequestration profile of receptor-trap approaches.

The clinical development hit several different populations. The hip fracture recovery trial (Becker group, Lancet 2015) showed modest improvements in lean mass and some functional measures in older adults recovering from surgery. The cachexia trials in pancreatic cancer and various other oncology populations showed muscle mass gains. The signal across these studies has been consistent: you can demonstrate hypertrophy in humans, the effect sizes are modest (smaller than receptor-level approaches), and translation to solid functional endpoints has been inconsistent.

What we find informative is the comparison across the antibody-only myostatin neutralizers. MYO-029, domagrozumab, landogrozumab, trevogrumab all produced detectable muscle mass effects but smaller magnitudes than ACE-031 or bimagrumab in healthy populations. That's mechanistically consistent with the idea that myostatin-only neutralization captures part of the pathway but leaves other ActRII ligand contributions (activin A, GDF-11) in play. The receptor-level approaches sweep more of the network.

The cancer cachexia work is honestly the most interesting near-term application for these antibodies. Sarcopenia in oncology patients is a real clinical problem, the muscle wasting has prognostic significance, and the data from the cachexia trials (including the ENGAGE pancreatic study) suggests measurable benefit for lean mass preservation. Whether that translates to survival or quality of life outcomes in larger trials is the open question.

Sourcing as a research antibody is essentially proprietary. Landogrozumab itself isn't broadly available, and research uses of anti-myostatin antibodies typically rely on alternative commercial reagents.

From a research perspective, landogrozumab adds to a coherent body of evidence that the myostatin pathway is real, druggable, and clinically tractable, but that the magnitude of effect from antibody-only myostatin neutralization is modest. For lab work on myostatin biology, more accessible reagents (and the genetic knockout models) are honestly more useful tools than the clinical antibodies.

Indication selection remains the central question for this class.

Evidence: 55
Mechanism: 78
Reliability: 60
Safety: 78
Sourcing: 35
Value: 38
Signal: 55
Staying power: 45

Plain-language summary Intrigue 48 / 100

Landogrozumab (LY2495655) is Eli Lilly's anti-myostatin antibody, built as an IgG4 isotype to reduce immune effector function compared to the IgG1 antibodies in the class. Phase 2 trials targeted cancer cachexia, hip-fracture-associated muscle wasting, and elective total hip arthroplasty recovery, all populations where preserving lean mass might affect functional outcomes. The trials produced muscle mass increases but limited functional benefit, echoing the pattern seen across the entire myostatin-blocking class. The program was discontinued. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Anti-myostatin monoclonal antibody

A humanized anti-myostatin monoclonal antibody developed at Eli Lilly; investigated for cancer cachexia and muscle wasting.

Abstract

Landogrozumab (LY2495655; humanized IgG4 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Eli Lilly. The IgG4 isotype reduces effector function (Fc receptor engagement, complement activation) compared to IgG1, theoretically reducing immunogenicity for chronic dosing. Phase 2 trials in cancer cachexia, hip-fracture-associated muscle loss, and statin-associated muscle pain demonstrated muscle mass increases of approximately 4 percent at 6 months but inconsistent functional improvement. Development has not advanced to phase 3. Used as a research compound for selective myostatin neutralization with reduced effector function.

Mechanism of action

Humanized IgG4 anti-myostatin monoclonal antibody; reduced Fc effector function compared to IgG1 anti-myostatin compounds.

Reported research dose ranges

Trial doses 50 to 300 mg subcutaneous.

References

Becker C, et al. Myostatin antibody (LY2495655) in older weak fallers. Lancet Diabetes Endocrinol 2015.
Golan T, et al. LY2495655, an antimyostatin antibody, in pancreatic cancer. ESMO Open 2018.
Latres E, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy. Skeletal Muscle 2015.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-362

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Landogrozumab

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs